Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

Background: Telazorlimab is a humanized anti-OX40 monoclonal antibody being studied for treatment of T-cell–mediated diseases. Objective: This randomized, placebo-controlled, phase 2b dose-range finding study investigated efficacy, safety, pharmacokinetics, and immunogenicity of telazorlimab in subj...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Barbara Rewerska, MD, Lawrence D. Sher, MD, Sady Alpizar, MD, Sylvia Pauser, MD, Grazyna Pulka, MD, Neelufar Mozaffarian, MD, PhD, Yacine Salhi, PhD, Camille Martinet, MS, Wafaa Jabert, MS, Girish Gudi, PhD, Vinu CA, MPharm, MSc, Sunitha GN, PhD, Julie Macoin, MSc, Victor Anstett, MS, Riccardo Turrini, PhD, Marie-Agnès Doucey, PhD, Stanislas Blein, PhD, Cyril Konto, MD, Martina Machkova, MD
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Elsevier 2024-02-01
Seri Bilgileri:Journal of Allergy and Clinical Immunology: Global
Konular:
Atopic dermatitis
anti-OX40 receptor
humanized monoclonal antibody
phase 2
telazorlimab
Online Erişim:http://www.sciencedirect.com/science/article/pii/S2772829323001200

Internet

http://www.sciencedirect.com/science/article/pii/S2772829323001200

Benzer Materyaller